Handelsavisen
prelaunch
Companies ›Healthcare ›BBOT.O
BB
BBOT.O — NASDAQ Biotechnology

BridgeBio Oncology Therapeutics Inc

$8,25
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-32,6 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$8,82
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

BridgeBio Oncology Therapeutics Inc is a biotechnology company operating in the Health Care sector, focused on developing oncology therapeutics.

Business. BridgeBio Oncology Therapeutics Inc (BBOT.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Wellington Management Company, LLP
largest disclosed fund holder
Profitability→
-32,6 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BBOT.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BBOT.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    BridgeBio Oncology Therapeutics Inc (BBOT.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    (a) BridgeBio Oncology Therapeutics Inc maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet is heavily weighted toward liquidity, with cash and equivalents totaling $373.7 million against total assets of $448.4 million. Total liabilities stand at $37.3 million, leaving total equity at $411.1 million. This strong liquidity position supports the company's low liquidity risk assessment.

    (b) The company is currently unprofitable, reporting a net income loss of $134.0 million and an operating income loss of $145.8 million. Consequently, return on equity is negative at -32.6%, and return on assets is negative at -29.9%. These metrics reflect the typical burn rate of a pre-revenue or early-stage biotechnology firm investing heavily in research and development rather than generating commercial returns.

    Key takeaways
    • The company holds a strong cash position of $373.7 million with zero debt, providing a substantial runway for operations.
    • Significant net losses of $134.0 million result in negative returns on equity (-32.6%) and assets (-29.9%).
    • Risk assessment flags are low for both liquidity and dilution, suggesting no immediate distress or aggressive share issuance.
    • Operating cash flow is negative at $113.9 million, highlighting the cash-intensive nature of current R&D activities.
    • No specific segment, geographic, or historical growth data is available to assess revenue diversification or trends.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $8,25
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $411.1M
    Net cashⓘ
    $373.7M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -29.9%
    ROEⓘ
    -32.6%
    Cash conversionⓘ
    85.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution11 analysts
    Strong buy4
    Buy7
    Hold0
    Sell0
    Strong sell0
    12-month price target$25,11 · Median $23,00
    Low $18,00High $41,00
    Operating income · consensus-197,1M USD
    EPS surprise
    −92,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$18,00
    Mean$25,11
    Median$23,00
    High$41,00
    Spot$8,25
    +204.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-32,6 %Above median
    D/E0,00Above median
    Cash Conv0,85Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 4 405 493 sh17 grants12 insiders
    • Chen BihuaDirector, 10% owner · Stock Option (Right to Buy) → Common StockAcquired 31 675 @ $7,73grant · 2026-06-16
    • Tipirneni Praveen P.Director · Stock Option (Right to Buy) → Common StockAcquired 31 675 @ $7,73grant · 2026-06-16
    • MCCORMICK FRANKDirector · Stock Option (Right to Buy) → Common StockAcquired 31 675 @ $7,73grant · 2026-06-16
    • Lebowitz Peter FDirector · Stock Option (Right to Buy) → Common StockAcquired 7 289 @ $7,73grant · 2026-06-16
    • Kelleher Raymond J.Director · Stock Option (Right to Buy) → Common StockAcquired 31 675 @ $7,73grant · 2026-06-16
    • Bauer JakeDirector · Stock Option (Right to Buy) → Common StockAcquired 31 675 @ $7,73grant · 2026-06-16
    • Kumar NeilDirector · Stock Option (Right to Buy) → Common StockAcquired 31 675 @ $7,73grant · 2026-06-16
    • Elmelech IdanCOO & Principal Financial Ofcr · Stock Option (Right to Buy) → Common StockAcquired 758 222 @ $7,66grant · 2026-05-10
    • Beltran PedroDirector, President and CEO · Stock Option (Right to Buy) → Common StockAcquired 1 103 837 @ $7,66grant · 2026-05-10
    • Lebowitz Peter FDirector · Stock Option (Right to Buy) → Common StockAcquired 63 350 @ $8,72grant · 2026-03-24
    • Mehra UneekChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 105 000 @ $10,19grant · 2026-03-10
    • Beltran PedroChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 210 000 @ $10,19grant · 2026-03-10
    • Ben YongChief Med & Dev Officer · Stock Option (Right to Buy) → Common StockAcquired 210 000 @ $10,19grant · 2026-03-10
    • Wallace Eli M.Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 1 114 400 @ $12,52grant · 2026-01-01
    • Wallace Eli M.Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 1 114 400 @ $12,44disposition · 2025-12-10
    • Wallace Eli M.Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 1 614 400 @ $12,44grant · 2025-10-02
    • MCCORMICK FRANKDirector · Stock Option (Right to Buy) → Common StockAcquired 91 076 @ $9,59grant · 2025-08-26
    • Tipirneni Praveen P.Director · Stock Option (Right to Buy) → Common StockAcquired 52 269 @ $9,59grant · 2025-08-26

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Assets
      net_income / total_assets
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. Market data — financials · 2026-07-27
    • reconciler_enqueue (reconciler) on BBOT.O · 2026-07-27

    Ownership & reference

    Top holders

    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$25M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$5M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$10M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$2M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$2M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

    Leadership

    • Neil KumarExecutive Chairman of the Board
    • Pedro J. BeltranPresident, Chief Executive Officer, Director

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $07 insiders · last 365d
    • Chen BihuaDirector, 10% owner · Common StockOther 1 704 862 · 2026-07-01
    • Cobo MarcPrincipal Accounting Officer · Common StockOther 125 @ $7,80$975 · 2026-07-01
    • Elmelech IdanCOO & Principal Financial Ofcr · Common StockOther 343 @ $7,80$3K · 2026-07-01
    • Beltran PedroDirector, President and CEO · Common StockOther 1 047 @ $7,80$8K · 2026-07-01
    • Chen BihuaDirector, 10% owner · Common StockOther 2 692 459 · 2026-07-01
    • Chen BihuaDirector, 10% owner · Common StockOther 4 528 186 · 2026-07-01
    • Ben YongChief Med & Dev Officer · Common StockOther 1 047 @ $7,80$8K · 2026-07-01
    • Chen BihuaDirector, 10% owner · Common StockOther 130 865 · 2026-07-01
    • Ben YongChief Med & Dev Officer · Common StockOther 1 047 @ $9,03$9K · 2026-04-01
    • Beltran PedroDirector, President and CEO · Common StockOther 1 047 @ $9,03$9K · 2026-04-01
    • Mehra UneekFormer Officer · Common StockOther 524 @ $9,03$5K · 2026-04-01
    • Beltran PedroChief Scientific Officer · Common StockOther 46 670 · 2026-03-10
    • Mehra UneekChief Financial Officer · Common StockOther 23 330 · 2026-03-10
    • Ben YongChief Med & Dev Officer · Common StockOther 46 670 · 2026-03-10
    • BridgeBio Pharma LLC10% owner · Common StockOther 784 720 · 2025-10-10

    Short positioning

    5.7Mshares short+9.1% vs prior
    12.6days to cover
    74.2%short of daily vol
    117.1Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BBOT.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Net income (annual): USD -134.04MUnknown
    • Current assets (annual): USD 432.4MUnknown
    • Operating income (annual): USD -145.82MUnknown
    • Total operating expenses (annual): USD 145.82MUnknown
    • Shares outstanding (annual): 79.99MUnknown
    • Capex (annual): USD 606KUnknown
    • Total assets (annual): USD 448.38MUnknown
    • Operating cash flow (annual): USD -113.89MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -4Unknown
    • EPS (diluted) (annual): USD-PER-SHARES -4Unknown
    • R&D expense (annual): USD 121.2MUnknown
    • Current liabilities (annual): USD 35.04MUnknown
    • Cash & equivalents (annual): USD 373.69MUnknown
    • Total liabilities (annual): USD 37.28MUnknown
    • Shareholders' equity (annual): USD 411.1MUnknown
    • Total liabilities (annual): USD 19.58MUnknown
    • Operating cash flow (annual): USD -55.03MUnknown
    • Shares outstanding (annual): 28.41KUnknown
    • Shareholders' equity (annual): USD -178.64MUnknown
    • Total operating expenses (annual): USD 80.86MUnknown
    • Operating income (annual): USD -80.86MUnknown
    • Net income (annual): USD -74.28MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -5.76KUnknown
    • Current liabilities (annual): USD 19.58MUnknown
    Showing 24 of 30 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-01INSIDERCobo Marc transacted 125 sh — Principal Accounting Officer ~$1k
    2026-07-01INSIDERBen Yong transacted 1.0k sh — Chief Med & Dev Officer ~$8k
    2026-07-01INSIDERChen Bihua transacted 4.53M sh — Director, 10% owner
    2026-07-01INSIDERChen Bihua transacted 1.70M sh — Director, 10% owner
    2026-07-01INSIDERChen Bihua transacted 130.9k sh — Director, 10% owner
    2026-07-01INSIDERElmelech Idan transacted 343 sh — COO & Principal Financial Ofcr ~$3k
    2026-07-01INSIDERBeltran Pedro transacted 1.0k sh — Director, President and CEO ~$8k
    2026-07-01INSIDERChen Bihua transacted 2.69M sh — Director, 10% owner
    2026-06-16 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative
    2026-06-16 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative
    2026-06-16INSIDERChen Bihua acquired 31.7k sh Stock Option (Right to Buy) — Director, 10% owner
    2026-06-16INSIDERKumar Neil acquired 31.7k sh Stock Option (Right to Buy) — Director
    2026-06-16INSIDERBauer Jake acquired 31.7k sh Stock Option (Right to Buy) — Director
    2026-06-16INSIDERKelleher Raymond J. acquired 31.7k sh Stock Option (Right to Buy) — Director
    2026-06-16INSIDERLebowitz Peter F acquired 7.3k sh Stock Option (Right to Buy) — Director
    2026-06-16INSIDERMCCORMICK FRANK acquired 31.7k sh Stock Option (Right to Buy) — Director
    2026-06-16INSIDERTipirneni Praveen P. acquired 31.7k sh Stock Option (Right to Buy) — Director
    2026-05-13FILING424B3 filing →
    2026-05-12FILING10-Q filing →
    2026-05-12FILING8-K filing →
    2026-05-10 00:00 UTCINSIDER2 insider transactions — 2026-05 2 derivative
    2026-05-10 00:00 UTCINSIDER2 insider transactions — 2026-05 2 derivative
    2026-05-10INSIDERElmelech Idan acquired 758.2k sh Stock Option (Right to Buy) — COO & Principal Financial Ofcr
    2026-05-10INSIDERBeltran Pedro acquired 1.10M sh Stock Option (Right to Buy) — Director, President and CEO
    2026-05-06FILING424B3 filing →
    2026-04-29FILING424B3 filing →
    2026-04-29FILING8-K filing →
    2026-04-28FILINGDEF 14A filing →
    2026-04-23FILING424B3 filing →
    2026-04-23FILING8-K filing →
    2026-04-01 00:00 UTCINSIDER3 insider transactions — 2026-04
    2026-04-01 00:00 UTCINSIDER3 insider transactions — 2026-04
    2026-04-01INSIDERBen Yong transacted 1.0k sh — Chief Med & Dev Officer ~$9k
    2026-04-01INSIDERBeltran Pedro transacted 1.0k sh — Director, President and CEO ~$9k
    2026-04-01INSIDERMehra Uneek transacted 524 sh — Former Officer ~$5k
    2026-03-26FILING424B3 filing →
    2026-03-26FILING8-K filing →
    2026-03-24 00:00 UTCINSIDER7 insider transactions — 2026-03 4 derivative
    2026-03-24 00:00 UTCINSIDER7 insider transactions — 2026-03 4 derivative
    Showing the 40 most recent of 54 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage